Skip to content
The Nexus
BUSINESSJul 6 · 20:52 UTCSTAT NEWSAllison DeAngelis

STAT+: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms

Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $10 billion, gaining access to its drug Palsonify for acromegaly and other drug candidates. The acquisition, valued at $85 per share, caused Crinetics' shares to rise 101% in after-hours trading.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Vertex PharmaceuticalsorganizationCrinetics PharmaceuticalsorganizationPalsonifytopicacromegalytopiccongenital adrenal hyperplasiatopicCrinetics sharestopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting